CureVac (NASDAQ:CVAC) Given Market Outperform Rating at JMP Securities

JMP Securities reissued their market outperform rating on shares of CureVac (NASDAQ:CVAC) in a research report report published on Monday morning, Benzinga reports. They currently have a $16.00 price objective on the stock.

CureVac Stock Down 4.9 %

CVAC stock opened at $3.27 on Monday. The company has a quick ratio of 2.28, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $732.09 million, a PE ratio of -2.46, a PEG ratio of 2.15 and a beta of 2.62. CureVac has a twelve month low of $2.21 and a twelve month high of $8.04. The stock has a 50-day simple moving average of $3.33 and a two-hundred day simple moving average of $3.28.

CureVac (NASDAQ:CVAC) last posted its earnings results on Thursday, August 15th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). The company had revenue of $15.55 million for the quarter, compared to analysts’ expectations of $10.07 million. CureVac had a negative net margin of 422.66% and a negative return on equity of 57.18%. On average, equities analysts predict that CureVac will post 0.05 EPS for the current fiscal year.

Institutional Trading of CureVac

Large investors have recently modified their holdings of the business. Ballentine Partners LLC bought a new stake in shares of CureVac during the 1st quarter valued at about $38,000. Bank of New York Mellon Corp bought a new stake in CureVac in the 2nd quarter worth approximately $54,000. Vanguard Personalized Indexing Management LLC bought a new stake in CureVac in the 4th quarter worth approximately $68,000. Signaturefd LLC lifted its position in CureVac by 232.0% in the 2nd quarter. Signaturefd LLC now owns 22,043 shares of the company’s stock worth $75,000 after buying an additional 15,403 shares during the last quarter. Finally, Aristides Capital LLC bought a new stake in CureVac in the 4th quarter worth approximately $100,000. Institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.